Banco Santander S.A. Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Banco Santander S.A. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 133,197 shares of the biopharmaceutical company’s stock after selling 26,647 shares during the quarter. Banco Santander S.A.’s holdings in Gilead Sciences were worth $14,768,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the last quarter. Nuveen LLC bought a new position in Gilead Sciences during the first quarter valued at $620,415,000. Finally, Nordea Investment Management AB increased its position in Gilead Sciences by 39.8% during the second quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company’s stock valued at $436,648,000 after acquiring an additional 1,126,886 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GILD. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Finally, Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.61.

Gilead Sciences Stock Up 0.2%

NASDAQ:GILD opened at $120.94 on Monday. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61. The company has a 50-day moving average of $115.47 and a 200 day moving average of $111.11. The firm has a market cap of $150.06 billion, a PE ratio of 24.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the firm earned $2.01 earnings per share. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,500 shares of company stock valued at $7,142,140 over the last three months. 0.27% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.